Population pharmacokinetics of cefepime in febrile neutropenia

implications for dose-dependent susceptibility and contemporary dosing regimens

Nathaniel J. Rhodes, Meagan E. Grove, Patrick J. Kiel, J. Nicholas O'Donnell, Laura K. Whited, Dusten T. Rose, David R. Jones, Marc H. Scheetz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Alterations in cefepime pharmacokinetic (PK) exposure and decreased bacterial susceptibility increase the risk of treatment failure. The impact of susceptible-dose-dependent (SDD) minimum inhibitory concentrations (MICs), i.e. 4–8 µg/mL, on target attainment rates for cefepime in febrile neutropenia (FN) is unclear. We sought to identify optimal cefepime regimens against SDD cefepime MICs in FN using a modelling and simulation approach. Creatinine clearance (CLCr) and body surface area (BSA) covariate-adjusted models of clearance were evaluated. Monte Carlo simulations representing 10 000 patients were completed to assess various dosing strategies (i.e. 3–8 g/day infused over 0.5–24 h, replaced every 6–24 h) and predict probabilities of target attainment (PTAs) for unbound cefepime. Nine patients received cefepime 2 g every 8 h (q8h) (0.5-h infusion). A two-compartment PK model with BSA- and CLCr-adjusted clearance was fit to the data. Mean population values for total clearance (6.3 ± 1.1 L/h), intercompartmental clearance (6.9 ± 2.8 L/h), and central (14.8 ± 3.8 L) and peripheral (10.9 ± 4.6 L) distribution volumes were all estimated with <50% CV. Simulated dosing regimens of 3–4 g/day administered as continuous infusions and doses of 2 g administered q6h (0–5 h infusion) to q8h (4-h infusion) achieved ≥90% PTA at MICs up to 8 µg/mL. Simulated regimens of 1 g q8h (4-h infusion) or 1 g q6h (0.5-h infusion) achieved ≥90% PTA only against MICs up to 4 µg/mL. High-dose prolonged infusion or more frequent cefepime regimens may be necessary to treat FN organisms with SDD MICs.

Original languageEnglish (US)
Pages (from-to)482-486
Number of pages5
JournalInternational Journal of Antimicrobial Agents
Volume50
Issue number3
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Febrile Neutropenia
Pharmacokinetics
Microbial Sensitivity Tests
Population
Body Surface Area
cefepime
Treatment Failure
Creatinine

Keywords

  • Cefepime
  • Febrile neutropenia
  • Pharmacology
  • Population pharmacokinetics
  • β-Lactams

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Population pharmacokinetics of cefepime in febrile neutropenia : implications for dose-dependent susceptibility and contemporary dosing regimens. / Rhodes, Nathaniel J.; Grove, Meagan E.; Kiel, Patrick J.; O'Donnell, J. Nicholas; Whited, Laura K.; Rose, Dusten T.; Jones, David R.; Scheetz, Marc H.

In: International Journal of Antimicrobial Agents, Vol. 50, No. 3, 01.09.2017, p. 482-486.

Research output: Contribution to journalArticle

Rhodes, Nathaniel J. ; Grove, Meagan E. ; Kiel, Patrick J. ; O'Donnell, J. Nicholas ; Whited, Laura K. ; Rose, Dusten T. ; Jones, David R. ; Scheetz, Marc H. / Population pharmacokinetics of cefepime in febrile neutropenia : implications for dose-dependent susceptibility and contemporary dosing regimens. In: International Journal of Antimicrobial Agents. 2017 ; Vol. 50, No. 3. pp. 482-486.
@article{fb9d8109bfa14a27a81be07e7cc0e625,
title = "Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens",
abstract = "Alterations in cefepime pharmacokinetic (PK) exposure and decreased bacterial susceptibility increase the risk of treatment failure. The impact of susceptible-dose-dependent (SDD) minimum inhibitory concentrations (MICs), i.e. 4–8 µg/mL, on target attainment rates for cefepime in febrile neutropenia (FN) is unclear. We sought to identify optimal cefepime regimens against SDD cefepime MICs in FN using a modelling and simulation approach. Creatinine clearance (CLCr) and body surface area (BSA) covariate-adjusted models of clearance were evaluated. Monte Carlo simulations representing 10 000 patients were completed to assess various dosing strategies (i.e. 3–8 g/day infused over 0.5–24 h, replaced every 6–24 h) and predict probabilities of target attainment (PTAs) for unbound cefepime. Nine patients received cefepime 2 g every 8 h (q8h) (0.5-h infusion). A two-compartment PK model with BSA- and CLCr-adjusted clearance was fit to the data. Mean population values for total clearance (6.3 ± 1.1 L/h), intercompartmental clearance (6.9 ± 2.8 L/h), and central (14.8 ± 3.8 L) and peripheral (10.9 ± 4.6 L) distribution volumes were all estimated with <50{\%} CV. Simulated dosing regimens of 3–4 g/day administered as continuous infusions and doses of 2 g administered q6h (0–5 h infusion) to q8h (4-h infusion) achieved ≥90{\%} PTA at MICs up to 8 µg/mL. Simulated regimens of 1 g q8h (4-h infusion) or 1 g q6h (0.5-h infusion) achieved ≥90{\%} PTA only against MICs up to 4 µg/mL. High-dose prolonged infusion or more frequent cefepime regimens may be necessary to treat FN organisms with SDD MICs.",
keywords = "Cefepime, Febrile neutropenia, Pharmacology, Population pharmacokinetics, β-Lactams",
author = "Rhodes, {Nathaniel J.} and Grove, {Meagan E.} and Kiel, {Patrick J.} and O'Donnell, {J. Nicholas} and Whited, {Laura K.} and Rose, {Dusten T.} and Jones, {David R.} and Scheetz, {Marc H.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.ijantimicag.2017.04.008",
language = "English (US)",
volume = "50",
pages = "482--486",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Population pharmacokinetics of cefepime in febrile neutropenia

T2 - implications for dose-dependent susceptibility and contemporary dosing regimens

AU - Rhodes, Nathaniel J.

AU - Grove, Meagan E.

AU - Kiel, Patrick J.

AU - O'Donnell, J. Nicholas

AU - Whited, Laura K.

AU - Rose, Dusten T.

AU - Jones, David R.

AU - Scheetz, Marc H.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Alterations in cefepime pharmacokinetic (PK) exposure and decreased bacterial susceptibility increase the risk of treatment failure. The impact of susceptible-dose-dependent (SDD) minimum inhibitory concentrations (MICs), i.e. 4–8 µg/mL, on target attainment rates for cefepime in febrile neutropenia (FN) is unclear. We sought to identify optimal cefepime regimens against SDD cefepime MICs in FN using a modelling and simulation approach. Creatinine clearance (CLCr) and body surface area (BSA) covariate-adjusted models of clearance were evaluated. Monte Carlo simulations representing 10 000 patients were completed to assess various dosing strategies (i.e. 3–8 g/day infused over 0.5–24 h, replaced every 6–24 h) and predict probabilities of target attainment (PTAs) for unbound cefepime. Nine patients received cefepime 2 g every 8 h (q8h) (0.5-h infusion). A two-compartment PK model with BSA- and CLCr-adjusted clearance was fit to the data. Mean population values for total clearance (6.3 ± 1.1 L/h), intercompartmental clearance (6.9 ± 2.8 L/h), and central (14.8 ± 3.8 L) and peripheral (10.9 ± 4.6 L) distribution volumes were all estimated with <50% CV. Simulated dosing regimens of 3–4 g/day administered as continuous infusions and doses of 2 g administered q6h (0–5 h infusion) to q8h (4-h infusion) achieved ≥90% PTA at MICs up to 8 µg/mL. Simulated regimens of 1 g q8h (4-h infusion) or 1 g q6h (0.5-h infusion) achieved ≥90% PTA only against MICs up to 4 µg/mL. High-dose prolonged infusion or more frequent cefepime regimens may be necessary to treat FN organisms with SDD MICs.

AB - Alterations in cefepime pharmacokinetic (PK) exposure and decreased bacterial susceptibility increase the risk of treatment failure. The impact of susceptible-dose-dependent (SDD) minimum inhibitory concentrations (MICs), i.e. 4–8 µg/mL, on target attainment rates for cefepime in febrile neutropenia (FN) is unclear. We sought to identify optimal cefepime regimens against SDD cefepime MICs in FN using a modelling and simulation approach. Creatinine clearance (CLCr) and body surface area (BSA) covariate-adjusted models of clearance were evaluated. Monte Carlo simulations representing 10 000 patients were completed to assess various dosing strategies (i.e. 3–8 g/day infused over 0.5–24 h, replaced every 6–24 h) and predict probabilities of target attainment (PTAs) for unbound cefepime. Nine patients received cefepime 2 g every 8 h (q8h) (0.5-h infusion). A two-compartment PK model with BSA- and CLCr-adjusted clearance was fit to the data. Mean population values for total clearance (6.3 ± 1.1 L/h), intercompartmental clearance (6.9 ± 2.8 L/h), and central (14.8 ± 3.8 L) and peripheral (10.9 ± 4.6 L) distribution volumes were all estimated with <50% CV. Simulated dosing regimens of 3–4 g/day administered as continuous infusions and doses of 2 g administered q6h (0–5 h infusion) to q8h (4-h infusion) achieved ≥90% PTA at MICs up to 8 µg/mL. Simulated regimens of 1 g q8h (4-h infusion) or 1 g q6h (0.5-h infusion) achieved ≥90% PTA only against MICs up to 4 µg/mL. High-dose prolonged infusion or more frequent cefepime regimens may be necessary to treat FN organisms with SDD MICs.

KW - Cefepime

KW - Febrile neutropenia

KW - Pharmacology

KW - Population pharmacokinetics

KW - β-Lactams

UR - http://www.scopus.com/inward/record.url?scp=85025826904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025826904&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2017.04.008

DO - 10.1016/j.ijantimicag.2017.04.008

M3 - Article

VL - 50

SP - 482

EP - 486

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 3

ER -